RUNX2 and breast cancer: Therefore, even if CADD522 is not strictly specific for RUNX2-DNA binding, the potential of CADD522 for BC therapeutics is still significant; CADD522 could be a strong anticancer drug due to its potential inhibition of both RUNX1 and RUNX2-DNA binding.